1
Pinkerton Anthony B, Davis Robert L, Gahman Timothy C, Semple Joseph E: Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase. Kalypsys, Pinkerton Anthony B, Davis Robert L, Gahman Timothy C, Semple Joseph E, HO Raymond J, March 1, 2007: WO/2007/025090 (114 worldwide citation)

The present invention relates to compounds useful as inhibitors of MEK kinase and methods for the treatment or prevention of cellular proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.


2
Gahman Timothy C, Lang Hengyuan, Davis Robert L, Scranton Shawn A: Inhibitors of b-raf kinase. Kalypsys, Gahman Timothy C, Lang Hengyuan, Davis Robert L, Scranton Shawn A, HO Raymond J, November 23, 2006: WO/2006/124874 (85 worldwide citation)

The present invention relates to compounds and methods useful as inhibitors of B-Raf for the treatment or prevention of cancer, including hematological and non-hematologic malignancies, hematopoiesis, autoimmune diseases, dermatologic and ophthalmologic conditions.


3
Gardiner Elisabeth M, Duron Sergio G, Massari Mark E, Severance Daniel L, Semple Joseph E: Cellular cholesterol absorption modifiers. Kalypsys, Gardiner Elisabeth M, Duron Sergio G, Massari Mark E, Severance Daniel L, Semple Joseph E, HO Raymond J, January 18, 2007: WO/2007/008541 (71 worldwide citation)

The present invention relates to compounds and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis.


4
SMITH NICHOLAS D: Heterocyclic modulators of gpr119 for treatment of disease. KALYPSYS, Bennett Dennis A, April 29, 2010: WO/2010/048149 (39 worldwide citation)

Disclosed herein are compounds and methods which may be useful as inhibitors of GPR 119 for the treatment or prevention of diseases including cardiovascular and metabolic diseases.


5
Gardiner Elisabeth M, Duron Wergio G, Massari Mark E, Severance Daniel L, Semple Joseph E, Smith Nicholas D: Celullar cholesterol absorption modifiers. Kalypsys, Gardiner Elisabeth M, Duron Wergio G, Massari Mark E, Severance Daniel L, Semple Joseph E, Smith Nicholas D, HO Raymond J, January 18, 2007: WO/2007/008529 (30 worldwide citation)

The present invention relates to compounds and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of cholesterol-related diseases, such as atherosclerosis.


6
Liu Kevin, Malecha James William, Noble Stewart Alwyn, Wash Paul L: Para-sulfonyl substituted phenyl compounds as modulators of ppars. Kalypsys, Liu Kevin, Malecha James William, Noble Stewart Alwyn, Wash Paul L, sBLAYLOCK Richard L, October 28, 2004: WO/2004/092117 (27 worldwide citation)

Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.


7
Lang Hengyuan, Gahman Timothy C, Davis Robert L, Scranton Shawn A: Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase. Kalypsys, Lang Hengyuan, Gahman Timothy C, Davis Robert L, Scranton Shawn A, GLOBAL PATENT GROUP, November 23, 2006: WO/2006/124780 (26 worldwide citation)

The present invention relates to compounds of formula IV and methods useful as inhibitors of B-Raf for the treatment or prevention of cancer, including hematological and non -hematologic malignancies, hematopoiesis, autoimmune diseases, dermatologic and ophthalmologic conditions, wherein G1 is selec ...


8
Smith Nicholas D, Bonnefous Celine, Zhuang Hui, Chen Xiaohong, Duron Sergio, Lindstrom Andrew: Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors. Kalypsys, Smith Nicholas D, Bonnefous Celine, Zhuang Hui, Chen Xiaohong, Duron Sergio, Lindstrom Andrew, BENNETT Dennis A, March 5, 2009: WO/2009/029617 (24 worldwide citation)

Novel diarylamine-substituted quinolone compounds and pharmaceutical compositions, certain of which have been found to inhibit inducible NOS synthase have been discovered, together with methods of synthesizing and using the compounds including methods for the treatment of iNOS-mediated diseases in a ...


9
Wash Paul L, Wiley Brandon M, Hassig Christian, Malecha James W, Noble Stewart A: Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease. Kalypsys, Wash Paul L, Wiley Brandon M, Hassig Christian, Malecha James W, Noble Stewart A, sBLAYLOCK Richard L, December 23, 2004: WO/2004/110418 (22 worldwide citation)

Disclosed herein are carbonyl compounds of Formula (I), (II) or (III), and others as described herein. Also disclosed are methods of treating disease, such as cancer, neurological disorders, including polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, autoimmune diseases ...


10
Gahman Timothy C, Thomas David J, Lang Hengyuan, Massari Mark E: Aminoquinazoline cannabinoid receptor modulators for treatment of disease. Kalypsys, Gahman Timothy C, Thomas David J, Lang Hengyuan, Massari Mark E, BENNETT Dennis A, December 24, 2008: WO/2008/157500 (21 worldwide citation)

The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and at ...